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BACKGROUND
Renée Dubois, a public health nurse consultant of fifteen years, sat at her desk at the Public
Health Agency of Canada, sipped her tea, and stared out the window. It was a beautiful spring
morning in Ottawa, Canada. From the corner of her eye, she noticed a red light flashing on her
landline and listened intently to the voicemails left on the Creutzfeldt-Jakob Disease
Surveillance System (CJDSS) phone line over the weekend. She listened to the first message,
then the second, and then the third. As the train of voicemails ended, her eyes widened. For the
first time in a decade, there had been a suspected outbreak of variant Creutzfeldt-Jakob
Disease (CJD) in Ontario.
Dr. Lawson, the referring doctor on the last voicemail, sounded calm despite the situation at
hand. “If you would please call me back as soon as possible, I would like to speak further about
the next steps.” Dr. Lawson is a neurologist at a well-known neurology center in Toronto, and
she called regarding a suspicious cluster of possible variant CJD cases in the Greater Toronto
Area. A set of five patients were displaying early symptoms of rapidly progressive dementia.
Noting that several of these patients were much younger than the typical age demographic
prone to sporadic CJD (Exhibit 1), Dr. Lawson immediately contacted the CJDSS to investigate
these cases as possible cases of variant CJD.
Upon receiving this information, Renée immediately sent out a department-wide email notifying
the other nurses of the situation. She had previous experience with a possible CJD outbreak a
decade prior. Luckily, the cases were not variant CJD (as confirmed by autopsy), and were
instead misdiagnosed cases of sporadic CJD. From this experience, Renée knew that the
consequences of an outbreak of variant CJD had wide ramifications, which required preplanning, inter-sectoral collaboration, and effective mobilization of resources to quickly diagnose
and isolate the source of a possible outbreak.
CREUTZFELDT-JAKOB DISEASE
Creutzfeldt-Jakob Disease (CJD) is a rapidly progressing, fatal, neurodegenerative disease. It is
the human form of bovine spongiform encephalopathy (BSE), popularized as “Mad Cow
Disease” in the early 2000s. The worldwide incidence of CJD is approximately one to two cases
per 1,000,000 persons (NCJDRSU, 2016). In Canada, this translates to 40-50 new cases per
year (Exhibit 2). Since 1994, there have been over 800 cases of confirmed CJD in Canada
(Exhibit 3), with a majority of cases in Ontario and Quebec (Exhibit 4).
DISEASE SYMPTOMOLOGY AND PROGRESSION
Creutzfeldt-Jakob Disease is characterized by the accumulation of prion proteins in the brain
and neural tissue degeneration, which gives the tissue a spongy appearance (PHAC, 2012).
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At onset, patients often experience psychiatric or sensory symptoms, including anxiety,
depression, visual hallucinations, and aphasia (WHO, 2012). As the disease rapidly progresses,
neurological defects develop within weeks, resulting in involuntary movements, dementia, and
ataxia (UCSF, 2016). The average duration of illness, from initial neurological symptoms to
death, can vary from four to 40 months (Kovács et al., 2005). At time of death, patients are
completely immobile and mute (WHO, 2012).
TYPES OF CJD
There are three types of CJD: sporadic, genetic, and acquired. In ~85% of patients, the disease
occurs sporadically, without any known external source of infection. This is referred to as
sporadic CJD. In 10% to 15% of patients, CJD develops in familial clusters, passed down
through inherited mutations of the prion protein gene PRNP. This type of CJD is referred to as
genetic CJD. Lastly, acquired CJD can develop in several ways and is the rarest form of CJD,
occurring in approximately 1% of patients. Acquired CJD is an umbrella term used to describe
iatrogenic CJD and variant CJD. As the name suggests, iatrogenic CJD is transmitted
iatrogenically, induced accidentally via hospital or diagnostic procedures. Iatrogenic CJD is
linked with exposure to contaminated hormones, infected dura mater or corneal grafts, and
contaminated neurosurgical instruments. However, variant CJD (vCJD) develops from the
ingestion of BSE-contaminated meats, or blood transfusions from a vCJD-positive donor (WHO,
2012; Budka & Will, 2015). WHO’s case definitions of CJD are presented in Exhibit 5.
PRIONS AS INFECTIOUS AGENTS
The prion protein (PrP) in its normal form is present in all humans and animals (WHO, 2011).
However, PrP is in an altered, self-propagating form in diseases like CJD and is referred to as a
prion or a proteinaceous infectious particle (Prusiner, 1998). When PrP is in its mutated form, it
is able to infect non-mutated forms of the protein, resulting in a cascade effect in the brain.
Contact with tiny amounts of prion-contaminated material can initiate the disease process in an
otherwise healthy individual. Once they appear, abnormal prion proteins aggregate. The
aggregation of proteins contributes to widespread neuron loss. However, the exact molecular
mechanism of this process is unknown (Clarke et al., 2001).
The altered form of PrP is responsible for a host of diseases including Kuru, Gerstmann–
Sträussler–Scheinker syndrome, and fatal familial insomnia (Will, 2003), with the latter two
implicated in genetic routes of transmission (Collins et al., 2001).
Certain surgical procedures can transmit prions. These include dura mater grafts, corneal grafts,
and any surgery involving neural tissues (PHAC, 2007). Prions can also be spread via exposure
to BSE-containing foods. However, there is no evidence that CJD can spread via social contact,
sexual contact, mother-to-child, blood transfusion, or through routine health care (PHAC, 2007).
CJD tissue infectivity is outlined in Exhibit 6.
A HISTORY OF VARIANT CJD IN CANADA AND WORLDWIDE
The earliest cases of vCJD were identified in 1994 in unexpectedly young individuals in the
United Kingdom (Will et al., 1996). Since then, over 200 cases of vCJD have been identified
worldwide, with 175 cases in the UK alone and 49 cases in other countries around the world –
including two in Canadian residents (WHO, 2012).
After 1996, the United Kingdom implemented strict food safety measures to prevent further
contamination in its food supply. Canada followed suit after the first Canadian case of vCJD was
identified in 2002 (Jansen et al., 2003).
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Furthermore, scientists discovered that several patients in the UK were infected with vCJDpositive blood via blood transfusion (Belay & Schonberger, 2005; WHO, 2008). This revelation
spurred many countries to take preventive measures to regulate their blood supplies and to
minimize the risk of vCJD being spread by blood transfusion. This remains true even today, as
Canadian Blood Services and Héma-Québec ensure that blood donations are not accepted
from individuals who may be silent carriers of CJD – for example, individuals who may have
lived a cumulative of three or more months in the United Kingdom between 1980 and 1996, or
five or more years in Western Europe from 1980 to 2007 (Héma-Québec, 2014).
Currently, the Government of Canada regulates the Canadian beef industry to minimize the risk
of BSE contamination. It has also minimized the risk of infection through surgical procedures
(PHAC, 2007) and through blood transfusion (Héma-Québec, 2014). By implementing various
infection-control guidelines, as outlined in the Creutzfeldt-Jakob Disease Quick Reference
Guide (PHAC, 2007), the risk of BSE infection in Canada is considered to be extremely low.
CREUTZFELDT-JAKOB DISEASE SURVEILLANCE
The Canadian Creutzfeldt-Jakob Disease Surveillance System (CJDSS) was established by
Health Canada in 1998 (PHAC, 2003), in response to the widespread outbreak of vCJD in the
United Kingdom. It was created as a national surveillance system for Creutzfeldt-Jakob
Disease. Currently, the role of the CJDSS is to assist in the investigation and diagnosis of
suspected cases of CJD in Canada, provide support to patients and health care providers, and
ultimately protect the health of Canadians by reducing the risk of CJD transmission.
Following the World Health Organization’s (WHO) model for comprehensive surveillance of
human prion diseases, the CJDSS offers support to collaborating health care professionals.
This is completed via initial consultation, referral for laboratory testing, provision of logistic
support, education, and awareness. With informed consent from patients, a detailed medical
chart review and family interviews are also completed. The resultant diagnostic and
epidemiological information gathered by the CJDSS is assembled in a comprehensive online
database and is used to support further epidemiological analysis and public health decisionmaking (PHAC, 2016).
HOW IS CJD DIAGNOSED?
Currently, there is no single definitive diagnostic test for CJD. However, if a patient is exhibiting
symptoms of CJD, there are several recommended laboratory tests that can be completed to
rule out more common causes of dementia or neurological symptoms, including encephalitis or
chronic meningitis (NINDS, 2003). Recommended laboratory testing for CJD is outlined in
Exhibit 7.
PUBLIC HEALTH CHALLENGES OF PRION DISEASES
Prion diseases like CJD pose a unique combination of challenges to public health. These
include their long incubation periods (upwards of a decade), a lack of host immunity, a strong
resistance to decontamination (for example, in neurosurgical instruments), limited diagnostic
testing, and potential for zoonotic and health care-based transmission (Coulthart et al., 2015).
Because the early symptoms of CJD are often non-specific, and the disease itself is quite rare, it
can be very difficult for physicians to diagnose. The disease also progresses quickly, and it can
be difficult for physicians to support families through the quick deterioration of their loved one.
Thus, it is important for public health to be aware of CJD and its risks and to be able to mobilize
resources to isolate and quarantine the source of a possible outbreak situation.
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BACK TO RENÉE – THE CASES AT HAND
After conducting an initial intake questionnaire with physicians and health care providers, Renée
amalgamated essential information regarding the five cases of suspected CJD, taking care to
note that all cases occurred within 50 km of Toronto. She recorded the patients’ dates of birth,
dates of onset, symptoms, and test results. She also noted rapidity of symptom progression.
Some initial test results are recorded in Exhibit 8. However, due to the varied availability of
equipment and quality of care experienced by Ontarians, not all recommended diagnostic tests
were completed prior to patient death (as in Case #3), while some results are still pending
(Case #4 and #5).
MASS MEDIA GETS THE SCOOP
Two weeks after Renée received the first voicemail from Dr. Lawson, Renée received word from
Dr. Lawson that the first patient of the five patients passed away. Mr. C. (Case #2) was a young,
prolific athlete, who was set to compete in the upcoming Olympics in Brazil. His rapidly declining
health was covered extensively in the public eye, with frequent posts to social media outlining
his deteriorating physical state.
Local reporters had begun flooding the neurology clinics and hospitals frequented by Mr. C.,
demanding answers. Several news outlets also released articles sensationalizing the potential
return of “Mad Cow Disease,” and imploring the federal government to intervene in the
investigation. Lobbyists began to spread sensationalized articles demanding a beef ban, and
Health Canada was being pressured to release a statement.
DEVELOPING AN INVESTIGATIVE STRATEGY: RENÉE’S DECISION
Renée tasked two nurses to compile the medical records and clinical information for each case.
Knowing the causes and methods of transmission of CJD, Renée struggled to come up with the
root cause of this outbreak. Without access to each patient’s medical history, she was struggling
to weave a connecting thread between the individual cases.
Renée needed to figure out the best course of action to lead the team of nurses to the correct
diagnosis. From her previous experiences working in a neurology clinic for 10 years, she was
very familiar with CJD diagnostic tests and how to interpret them. What were the best diagnostic
tests for her to pursue? What were some potential root causes she could suggest the team to
concentrate on to direct their investigation? Were these cases connected? If so, what should
she do next?
A confident speaker, Renée often presented about CJD at universities and conferences across
Canada. From her experiences as a keynote speaker, Renée knew that referring to CJD as
“Mad Cow Disease” would merely fan the flames of public hysteria. Reducing the
sensationalized stories in the media was her first goal.
In the case of Mr. C., what essential information should Renée recommend that the hospitals
and neurology clinics share to the media? What should Renée’s main message be? Who should
Renée collaborate with to get her message out to the public? What cautionary information
should the public campaign include?
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EXHIBIT 1
Distribution of Variant and Sporadic CJD Cases in the UK, by Age

Source: Will, 2003. Reproduced with permission from Robert G. Will. Acquired Prion Disease: Iatrogenic
CJD, Variant CJD, Kuru. British Medical Bulletin (2003) 66 (1): 255-265. Published by Oxford
University Press online at: https://academic.oup.com/bmb/article/66/1/255/284826/Acquiredprion-disease-iatrogenic-CJD-variant-CJD?searchresult=1 For permissions please email:
journals.permissions@oup.com.
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EXHIBIT 2
Incidences of CJD in Canada: 1999-2016
As of June 30, 2016

Source: PHAC, 2016.
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EXHIBIT 3
CJD Deaths Reported by the CJD Surveillance System (1994-2016)
As of June 30, 2016

Source: PHAC, 2016.
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EXHIBIT 4
Map of CJD Cases in Canada
As of June 30, 2016

Source: PHAC, 2016.
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EXHIBIT 5
Case Definitions of CJD
At time of death, all possible CJD cases in Canada are classified according to the WHO
diagnostic criteria for CJD:
Definite CJD
- Requires neuropathologic examination
- Confirmed by cranial autopsy
Probable CJD
- Case is lacking neuropathologic examination
- Based on combination of non-neuropathologic criteria:
 Clinical profile (ataxia, rapid progressive dementia, etc.)
 Results of cerebrospinal fluid (CSF) protein immunoassays
 EEG
 MRI
 Genetic analysis
 Brain/tonsil biopsy
Possible CJD
- Information is even more limited.
Source: WHO, 2008.
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EXHIBIT 6
CJD Tissue Infectivity
High Infectivity
‐ Brain
‐ Cerebrospinal fluid
‐ Dura mater
‐ Pituitary gland
‐ Posterior eye
‐ Spinal cord and ganglia
‐ Trigeminal ganglia
No Detected Infectivity
‐ Adipose tissue
‐ Adrenal gland
‐ Appendix
‐ Blood (including cord blood)
‐ Blood vessels
‐ Bone marrow
‐ Breast milk
‐ Dental pulp
‐ Epididymis
‐ Esophagus
‐ Feces
‐ Gingival tissue
‐ Heart
‐ Ileum
‐ Jejunum
‐ Large intestine
‐ Nasal mucosa
‐ Nasal mucous
‐ Ovary

Low Infectivity
‐ Cornea
‐ Kidney
‐ Liver
‐ Lung
‐ Lymph nodes
‐ Placenta
‐ Spleen
‐
‐
‐
‐
‐
‐
‐
‐
‐
‐
‐
‐
‐
‐
‐
‐
‐
‐
‐

Source: PHAC, 2007.
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Pancreas
Pericardium
Peripheral nerves
Placental fluids
Prostate
Saliva
Semen
Seminal vesicle
Skeletal muscle
Skin
Sweat
Tears
Testis
Thymus
Thyroid gland
Tongue
Tonsil
Trachea
Urine
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EXHIBIT 7
Recommended Laboratory Testing for CJD
Upon initial intake of a patient, it is recommended that the following tests be conducted in order
to confirm or rule-out the possibility of CJD:
1. CEREBROSPINAL FLUID (CSF) TESTING
In all cases of CJD, CSF testing is highly recommended. CSF is collected via lumbar
puncture and is tested for levels of various proteins. Some protein tests that are conducted
using CSF include 14-3-3, S100B, and tau protein tests (Coulthart et al., 2011). Elevated
levels of these proteins have been reported to support a CJD diagnosis. However, each test
has varying levels of sensitivity and specificity, and the threshold limits of each protein can
differ from patient to patient. Currently, CSF tau shows the best overall diagnostic accuracy,
compared to 14-3-3 or S100B protein markers (Coulthart et al., 2011).
2. COMPUTERIZED TOMOGRAPHY (CT) SCANS
Computerized tomography (CT) scans of the brain can sometimes rule out the possibility
that exhibited symptoms may have resulted from another neurological issue including
strokes or tumours in the brain (WHO, 2008).
3. ELECTROENCEPHALOGRAPHY (EEG)
Electroencephalography (EEG) measures waves of electrical activity in the brain. This test
can be valuable as certain sharp wave complexes are characteristic in sporadic CJD.
However, EEG is not useful in the diagnosis of vCJD (WHO, 2008).
4. MAGNETIC RESONANCE IMAGING (MRI)
Magnetic resonance imaging (MRI) brain scans also can reveal characteristic patterns of
brain degeneration that can help diagnose CJD (WHO, 2008).
5. GENETIC TESTING
Blood samples can be used to prepare DNA for genetic analysis. Specific mutations in the
PRNP gene, including P102L, E200K and D178, are CJD-causing variations. However,
some variations are silent, and do not cause disease – for example, M129V (Swietnicki et
al., 1998).
6. TONSIL BIOPSY
Prion proteins can often be found in tonsil tissues in CJD-positive patients. However, this
test is not useful in diagnosing sporadic or genetic CJD (WHO, 2008).
7. BRAIN AUTOPSY
While the results of the aforementioned six diagnostic tests may lead to a strong diagnosis
of CJD, the only definite method of knowing whether the patient has CJD is through brain
autopsy at time of death. However, autopsy is a lengthy process, requiring several months
to complete. Some characteristic changes in a CJD-positive brain include:
 Spongiform change
 Loss of neurons
 High astrocyte density
 Presence of abnormal prion proteins
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EXHIBIT 8
Case Characteristics and Test Results
Case #
1
2
3
4
5

Age at Onset
42
25
33
44
36

CSF Results
Positive
Positive
Pending
Positive
Pending

EEG
Negative
Negative
Unknown
Negative
Negative

Source: Created by author.
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MRI
Negative
Positive
Unknown
Pending
Pending

Status
Alive
Dead
Dead
Dead
Alive
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BACKGROUND
A suspected cluster of variant Creutzfeldt-Jakob Disease (CJD) cases (a fatal
neurodegenerative disease) has been identified in Toronto. Renée Dubois, a public health
nurse, must utilize epidemiological data to recognize the outbreak, and mobilize resources to
support patients and health care providers. The assembled epidemiological information
gathered by the CJD surveillance system must be used to further support data analysis, public
health decision-making, and public messaging. This case may be used to supplement lectures
covering relevant public health events or epidemic analysis.
OBJECTIVES
1. Understand the importance of case reporting and laboratory data for surveillance of
infectious diseases and outbreak detection.
2. Identify limitations of diagnostic tests and laboratory data, as well as the importance of
ethical guidelines and informed consent in patient sampling.
3. Devise an emergency preparedness management strategy in the event of a communicable
disease outbreak.
4. Interpret epidemiological data to understand the spread, origin, and effects of communicable
disease.
5. Interpret laboratory data in context of epidemiological data in order to make
recommendations for timely public health action.
DISCUSSION QUESTIONS
1. What is an outbreak?
a. What are some modern examples of outbreaks?
2. How can you recognize an outbreak?
3. What sources of information would you consult to confirm that it is an outbreak?
a. How would you access this information?
b. What are the limitations of diagnostic tests and laboratory data?
4. What information is most relevant for public health decision-making?
5. What is the role of media in outbreak investigation and communication?
a. How do you ensure confidentiality in a high profile outbreak?
b. What is the public message you would communicate, and what would that look like?
 Relate this to current public health events.
KEYWORDS
Epidemiology; Creutzfeldt-Jakob Disease (CJD); outbreak management; surveillance data;
PHAC.
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